硝唑尼特和阿苯达唑联合治疗小鼠原发性和继发性泡状棘球蚴病的机制探讨

目的观察硝唑尼特、阿苯达唑及硝唑尼特／阿苯达唑联合治疗原发性和继发性泡状棘球蚴病小鼠的疗效。方法分别通过腹腔注射泡状棘球蚴原头节和口服泡状棘球蚴虫卵的方式建立继发性和原发性泡状棘球蚴病小鼠模型，建模2个月后分别进行药物治疗，药物经口灌胃，疗程持续35d后，检测各组小鼠泡状棘球蚴囊湿重及病理改变并检测血清IL-2、IL-4、TNF—α和Ig—E的含量。结果治疗35d后，继发性泡球蚴感染小鼠用药组与模型对照组比较，用药组泡球蚴的平均湿重显著下降（P〈0．01），结果现示硝唑尼特单独及联合均有明显抑制小鼠泡状棘球蚴生长的作用（抑囊率分别为51．56％、67．68％、88．06％），其中联合用药明显优于单独用药。继发性和原发性泡球蚴感染实验小鼠血清IL-2、IL-4及Ig-E的含量，用药组和模型对照组比较差异有统计学意义（P〈0．01），与空白对照组比较差异无统计学意义（P〉0．05）；TNF—α含量用药组和模型对照组与空白对照组比较差异有统计学意义（P〈0．05），用药组与模型对照组比较差异有统计学意义（P〈0．05）。结论硝唑尼特及硝唑尼特／阿苯达唑联合用药对小鼠泡状棘球蚴感染有一定的抑制作用。

Anti-parasitic activity on second and primary murine alveolar echinococcosis with combined treatment of albendazole/nitazoxanide

To observe combined albendazole/nitazoxanide therapy inhibit anti-parasititic effect on murine secondary and primary alveolar echinococcosis and discuss mechanism of the anti-parasititic activity. The efficacies of chemotherapy employing nitazoxanide（NTZ） ,albendazole（ABZ）, and NTZ/ABZ combination against alveolar echinococcosis were investigated in an experimental murine model. Following secondary and primary infection,meaning mice were i. p. injection of Echinococcus multilocularis metacestodes and orally infected with Echinococcus multilocularis eggs. Treatment was started either immediately at 2 months and the drugs were administered by intragastric inoculation on a daily bases for a period of 35 days. Parasite weight and histopathological change of cyst were observed . Meanwhile these mice were taken blood from their eyeballs after 35 days treatment. Then the contents of IL-2,IL-10,TNF-α and Ig-E was detected. It was found that therapeutics groups were proven to be significantly more effective in terms of reducing parasite weight after treatment（P〈0.01）. In vivo experiments showed that nitazoxanide alone, ABZ alone and nitazoxanide combined with ABZ had obviously inhibitory effect on growth of secondary alveolar echinococcosis cyst （inhibition rates were 51.56 %, 67.68 %,88.06% respectively）. The levels of IL-2, IL 4 and Ig-E in serum in secondary and primary murine infection model were significantly different from these therapeutics groups and the disease model group （P〈0.01）. There were no significant difference between these therapeutics groups and the blank group （P〉 0.05）. The serum TNF-α of therapeutics groups and disease model groups were significantly different from the blank group （P 〈0.05）and there were also significant difference between these therapeutics groups and the disease model groups （P〈0.05）.It is concluded that the potential value for NTZ and/or a combined ABZ/NTZ chemotherapy against alveolar echinococcosis exists.